STOCK TITAN
  1. Home
  2. News
  3. SLP

Simulations Plus Inc. - SLP STOCK NEWS

Welcome to our dedicated news page for Simulations Plus (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Simulations Plus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Simulations Plus's position in the market.

News
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
Rhea-AI Summary
Simulations Plus, Inc. (SLP) announces the FDA renewal of DILIsym software licenses, a key tool for predicting drug-induced liver injury risk. The software aids in evaluating potential DILI risk, understanding compound mechanisms, and tailoring dosing strategies for efficacy and safety. Dr. Watkins highlights the importance of predicting safe dosing regimens for effective therapies. The incorporation of quantitative systems pharmacology and toxicology models by the FDA showcases the industry's shift towards advanced evaluation tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.61%
Tags
none
-
News
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Rhea-AI Summary
Simulations Plus (SLP) reports strong financial results for Q2 fiscal 2024, with total revenue of $18.3 million and diluted EPS of $0.20. The company maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68. Revenue increased by 16% compared to Q2 2023, driven by growth in software and services segments. The company's management remains optimistic about future demand and strategic investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.61%
Tags
earnings
-
News
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) will announce its second-quarter fiscal 2024 financial results on April 3, 2024, after the market closes. A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
earnings
News
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Rhea-AI Summary
Simulations Plus, Inc. (SLP) CEO to host fireside chat at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum. Live webcast available for replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences
-
News
Simulations Plus and the University of Bath Awarded New FDA Grant
Rhea-AI Summary
Simulations Plus, Inc. (SLP) partners with the University of Bath and other institutions to develop an enhanced dermal PBBM/PBPK model for topical products, funded by the FDA. The collaboration aims to revolutionize drug product performance prediction, expedite regulatory decisions, and benefit patients and the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
-
News
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
Rhea-AI Summary
Simulations Plus extends agreement with NIEHS for research project on chemical safety assessment utilizing computational tools like ADMET Predictor and GastroPlus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
News
Simulations Plus Launches Corporate Development Initiative
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces a strategic shift towards investing in early-stage companies to drive innovation and collaboration. The company aims to enhance innovation, grow its M&A pipeline, expand revenue opportunities, and drive shareholder returns through strategic investments and partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.63%
Tags
none
-
News
Simulations Plus to Participate in Upcoming Healthcare Conferences
Rhea-AI Summary
Simulations Plus, Inc. (SLP) will participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference virtually from February 13-14, 2024. CEO Shawn O’Connor will present on February 13 at 11:20 a.m. Eastern Time. The live webcast will be available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
News
Simulations Plus Releases GastroPlus® Version 9.9
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) announces the release of GastroPlus® 9.9, featuring expanded models for ocular, oral cavity, and dermal delivery routes, improved Biologics Module, and upgraded ADMET Predictor® version 11 models. The company collaborated with the FDA and other regulatory agencies, incorporating feedback from over 100 companies to enhance the software. The updates aim to improve the functionality and predictive capabilities of the platform, supporting program design and regulatory submissions for pharmaceutical industry and clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
News
Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
Rhea-AI Summary
Simulations Plus, Inc. (SLP) has been awarded a new funded grant from the U.S. Food and Drug Administration (FDA) to aid in the understanding of oral modified-release (MR) formulations and advance the development and approval of generic oral MR drug products through a joint proposal with Northeastern University and The TIM Company. The project will integrate experimental data and PBPK modeling to identify key formulation factors to accelerate modified-release product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
Stock SLP logo
Simulations Plus Inc.

Nasdaq:SLP

SLP Rankings

#2473 Ranked by Market Cap
#3207 Ranked by Stock Gains
#1993 Ranked by Dividends

SLP Stock Data

929.70M
16.19M
18.89%
78.83%
6.01%
Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
US
Lancaster

About SLP

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res